Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • FDA acts to encourage...

    FDA acts to encourage generic competition for complex drugs

    Written by Ruby Khatun Khatun Published On 2017-10-04T10:46:43+05:30  |  Updated On 13 Aug 2021 12:48 PM IST

    TRENTON, N.J.: The U.S. Food and Drug Administration (FDA) is opening a new front in its efforts to reduce high drug prices by encouraging the development of generic versions of hard-to-make medicines.


    Complex drugs and drug-device combinations generally are very expensive and some are widely used. Often, they don't get generic competition right after their patent expires, as happens routinely with pills.


    Difficulty in creating copies or near-copies of such drugs and getting them approved may deter generic companies from even trying, FDA Commissioner Dr. Scott Gottlieb wrote in a blog post.


    That means patients don't get access to cheaper versions of those drugs and the brand-name medicine makers continue to rake in money, often billions of dollars a year per drug.


    To get more generic versions of complex drugs on the market, the FDA will begin giving companies guidance on how to win approvals, including offering meetings with agency staff early on, to shorten the time for development and approval.


    Examples of older complex drugs cited by Gottlieb that still lack generic competition include the Advair inhaler and injected medicines Forteo for osteoporosis, Victoza for high blood sugar and Copaxone for multiple sclerosis.


    Their monthly costs without insurance range from about $400 for Advair to up to $5,200 for Copaxone. A generic version of Copaxone was approved in 2015, but it's not yet on sale because the maker hasn't met FDA's manufacturing standards.


    "This is a shot across the bow" to the brand-name companies, said analyst Steve Brozak, president of WBB Securities.


    Gottlieb's close ties to drugmakers worried consumer groups when he was nominated. Now, Brozak said, he's telling brand-name drugmakers to focus on developing new drugs, not wringing extra money out of blockbusters long on the market, while encouraging generic makers.


    "Nothing in healthcare is instantaneous," Brozak said, but Gottlieb "is starting to build a roadmap for how to prove" a generic is equivalent to a complex brand-name drug.


    Longer-term plans include coming up with new, better tools to determine if a proposed copycat of a complex injected drug really will affect patients the same way.


    The FDA has already made changes to increase competition including reducing a backlog of generic pills that were awaiting approval and addressing some loopholes brand-name makers use to delay competition.

    Advaircompetitioncomplex drugsCopaxoneDr Scott GottliebDrugmakersencourageFDAForteogenericgeneric versionshigh blood sugarhigh drug pricesinhalermultiple sclerosisosteoporosisU.S. Food and Drug AdministrationVictoza
    Source : AP

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok